Business Description
Tevogen Bio Holdings Inc. is a clinical-stage biotech company founded in 2020 and based in Warren, New Jersey, focused on creating ready-to-use T cell treatments for infectious diseases, cancer, and other serious conditions. Its lead therapy, TVGN 489, has been tested in Phase 1 trials for COVID-19 and related complications, including Long COVID and cases involving immune-suppressed patients. The company also has several treatments in early-stage research targeting cervical cancer, throat cancer, multiple sclerosis, Epstein-Barr virus-related lymphomas, and hepatitis B.
